Purpose: To determine the clinical efficacy of epirubicin plus docetaxel or paclitaxel in management breast cancer. 
 Methods: This study was a randomized controlled trial that recruited 78 patients with cancer treated The First People’s Hospital Anqing between December 2018 and March 2021. participants were to receive either (control group) (study group), 39 cases each group. Clinical out...

BACKGROUND The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). METHODS Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of bra...

Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Ramucirumab plus docetaxel became one the available options for subsequent treatment in NSCLC after REVEL study. In addition, immune-checkpoint inhibitors (ICIs) standard NSCLC. Combining ICIs with anti-vascular endothelial growth factor blockade many tries to overcome resistance. We present our real-world data ramuciruma...

Aim: Prostate cancer is the second leading cause of death in cancer-related deaths men. Docetaxel and abiraterone acetate are widely used treatment castration-resistant metastatic prostate cancer. Phospho-PTEN triggers proliferation, migration, angiogenesis survival cells by causing oncogenic Akt hyperactivation. This study, it aimed to investigate effects docetaxel agents, which cancer, on exp...

Abstract Background Mesenchymal stem cells (MSCs) have been proved to drive castration resistant prostate cancer (CRPC). In this study, we aim investigate the contribution of MSCs development docetaxel resistance in CRPC and its potential mechanisms. Methods The effect on was determined using vivo vitro approaches. CCK8 PI/Annexin V-FITC assay were used examined cell viability apoptosis. concen...

Docetaxel belongs to the taxane family of anti-cancer drugs, which are commonly used in non-small cell lung cancers. They stabilize microtubules by preventing depolymerization, resulting in cell death. Pneumonitis is an uncommon side effect of docetaxel. We report a case of docetaxel induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with metastatic adenocar...

aims: the backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. we intended to compare the effectiveness of two commonly used regimens in real world practice. methods: this single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage iiib, iv) non-small cell lung cancer and eastern cooperative o...

objective(s): chemoresistance remains the main causes of treatment failure and mortality in cancer patients. there is an urgent need to investigate novel approaches to improve current therapeutic modalities and increase cancer patients' survival. induction of drug efflux due to overexpression of                  p-glycoproteins is considered as an important leading cause of multidrug resis...

OBJECTIVES To describe characteristics associated with neurotoxicity (NT) in advanced ovarian cancer patients treated on Gynecologic Oncology Group 218 and examine effect of substituting docetaxel for paclitaxel in these patients. METHODS The development of NT was defined as Common Toxicity Criteria grade (G)≥1. The association between substitution with docetaxel and NT improvement was explor...

BACKGROUND This study was conducted in order to elucidate the effects of docetaxel on the growth of peroxiredoxin 1 (Prx1) knockdown A549 xenograft tumors and further tested the role of Prx1 as a predictor for how a patient would respond to docetaxel treatment. METHODS Effects of docetaxel on the growth of scrambled- and shPrx1-infected A549 xenograft tumors in nude mice were measured. Moreov...